EN | TR
E-ISSN: 1307-5608
Investigation of Molecular Changes in RAS/RAF/MEK/MAPK Pathway in Serous Adenocarcinomas and Serous Borderline Tumors of Ovary
PDF
Cite
Share
Request
Research Article
VOLUME: 73 ISSUE: 2
P: 144-148
August 2020

Investigation of Molecular Changes in RAS/RAF/MEK/MAPK Pathway in Serous Adenocarcinomas and Serous Borderline Tumors of Ovary

J Ankara Univ Fac Med 2020;73(2):144-148
DOI: 10.4274/atfm.galenos.2020.13007
Cevriye Cansız Ersöz
1. Ankara Üniversitesi Tıp Fakültesi, Tıbbi Patoloji Anabilim Dalı, Ankara, Türkiye
No information available.
No information available
Received Date: 21.11.2019
Accepted Date: 28.02.2020
Publish Date: 21.07.2020
PDF
Cite
Share
Request

ABSTRACT

Objectives:

To investigate MAP Kinase (p38), c-Fos, c-Jun and c-Myc; in RAS/RAF/MEK/MAPK pathway by immunohistochemically in high grade serous adenocarcinomas, serous borderline tumors and benign lesions of the ovary.

Materials and Methods:

Twelve serous borderline tumors, 41 high-grade serous carcinomas and 19 cases of serous papillary cystadenofibromas, serous cystadenomas; p38, c-Myc, c-Jun and c-Fos immunohistochemical staining were performed.

Results:

In borderline and benign lesions, diffuse and severe staining was observed in all cases with c-Fos, whereas focal and mild staining was observed in only 16 of the serous adenocarcinomas (p<0.05). While nuclear staining was not observed in any of the serous adenocarcinomas with c-Myc, mild and focal staining was detected in four of the borderline tumors and 16 of the benign tumors. There was a statistically significant difference in nuclear staining between the three groups (p<0.05). Nuclear staining was detected in four borderline tumors, in seven serous adenocarcinomas and in eight cases in the benign tumor group with c-Jun. These stainings were not statistically significant. Moderate staining was observed in 18 of benign tumors and in all borderline tumors and mild staining in eight of serous adenocarcinomas. A statistically significant difference was found between benign and serous borderline tumors and serous adenocarcinomas (p<0.05); there was no difference between benign tumors and borderline tumors.

Conclusion:

In borderline serous tumors; the nuclear expression of p38, c-Myc and c-Fos is statistically different from serous adenocarcinomas that proves the activation of the RAS/RAF/MEK/MAPK pathway in borderline tumors. In practical life, although it may seem usable in the cases that these tumors cannot be separated from serous adenocarcinoma; that we could not include in this study; the staining pattern in low-grade serous adenocarcinomas is unknown. Therefore, it should be investigated in large case series whether low grade serous adenocarcinomas and borderline tumors show similar expression patterns.

Keywords: Ovary, Serous Tumors, RAS/RAF/MEK/MAPK Pathway

REFERENCES

1ShihIe M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511-1518.
2Kurman RJ, Carcangiu ML, Herrington S, Young RH eds 4. IARC; Lyon, France: 2014. WHO classification of tumours of female reproductive organs
3Kurman RJ, ShihIe M. The Dualistic Model of Ovarian Carcinogenesis; Revisited, Revised, and Expanded. Am J Pathol. 2016;186: 733-747.
4Singer G, Oldt R, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Nat Cancer Inst. 2003;95:484-486.
5Kuo KT, Guan B, Feng Y, et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res. 2009;69:4036-4042.
6Pohl G, Ho CL, Kurman RJ, et al. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res. 2005;65:1994-2000.
7Kurman RJ, Vang R, Junge J, et al. Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Am J Surg Pathol. 2011;35:1605-1614.
8Jones S, Wang TL, Kurman RJ, et al. Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol. 2012;226:413-420.
9Howitt BE, Hanamornroongruang S, Lin DI, et al. Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma. Am J Surg Pathol. 2015;39:287-293.
10Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 2015;521:489-494.
11Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195:451-456.
12Finch A, Beiner M, Lubinski J, et al. Hereditary Ovarian Cancer Clinical Study Group Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006;296:185-192.
13Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30:230-236.
14Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood. 2003;101:4667-4679.
15Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J. 2010,429:403-417.
16Stachowiak MK, Sar M. Stimulation of adrenal medullary cells in vivo and in vitro induces expression of c-FOS protooncogene. Oncogene. 1990;5:69-73.
17Franchi A. Immunohistochemical detection of c-FOS and c-JUN expression in cartilaginous tumours of the skelaton. Virchows Arch. 1998;432:515-519.
18Cavigelli M, Dolfi F. Induction of c-FOS expression through JNK-mediated TCF/Elk-1 phosphorylation. EMBO J. 1995;14:5957-5964.
19Mok SC, Bell DA, Knapp RC, et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res. 1993;53:1489-1492.
20Chung-Liang Ho. Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors. Cancer Research. 2004;64.:6915-6918.
21Chen L, Mayer JA, Krisko TI, et al. Inhibition of the p38 kinase suppresses the proliferation of human ER negative breast cancer cells. Cancer Res. 2009;69:853-861.
22Halawani D, Mondeh R, Stanton LA et al. p38 MAP kinasesignaling is necessary for rat chondrosarcoma cell proliferation. Oncogene. 2004;23:3726-3731.
23Recio JA, Merlino G. Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene. 2002;21:1000-1008.
24Hari K. Koul, Mintu Pal, Sweaty Koul. Role of p38 MAP Kinase Signal Transduction in Solid Tumors. Genes & Cancer. 2013;4:342-359.
25Oliveira-Ferrer L, Ro K, Haustein V, et al. c-FOS suppresses ovarian cancer progression by changing adhesion. British Journal of Cancer. 2014;110:753-763.
26Silverberg SG, Sasano H. Immunolocalization of c-myc oncoprotein in mucinous anda serous adenocarcinomas of the ovary; Hum Pathol. 1992;23:491-495.
27Jing S, Xin C, Mingo MH Y, et al. miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer. Oncogene. 2019;38:564-580.
28Nagarajae AB, Josepha P, Kovalenkob O, et al. Evaluating class III anti arrhythmic agents as novel MYC targeting drugs in ovarian cancer. Gynecol Oncol. 2018;151:525-532.
2024 ©️ Galenos Publishing House